Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2022 | $14.00 | Mkt Perform → Outperform | Barrington Research |
| 7/20/2022 | $13.00 | Overweight | Stephens |
| 4/6/2022 | Outperform → Mkt Perform | Barrington Research | |
| 10/4/2021 | $15.00 → $14.00 | Buy | Roth Capital |
| 7/30/2021 | $12.00 → $15.00 | Buy | Roth Capital |
Lifecore segment revenues increased 8.0% to $23.7 million in fiscal 2023 first quarter versus the prior year periodLifecore segment EBITDA increased 8.1% to $2.5 million in fiscal 2023 first quarter versus the prior year periodReiterates fiscal 2023 full year guidance for LifecoreCorporate rebranding to Lifecore Biomedical continues to progress SANTA MARIA, Calif. and MINNEAPOLIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), reported results for the fiscal 2023 first
SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced a change to its previously announced fiscal 2023 first quarter earnings conference call date in recognition of Yom Kippur. The Company will now report financial results before the market opens on T
SANTA MARIA, Calif. and MINNEAPOLIS, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Landec" or the "Company"), a diversified health and wellness company focused on its growing Lifecore Biomedical ("Lifecore") business – a fully integrated contract development and manufacturing organization ("CDMO") that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials – today announced that it will host a conference call to discuss fiscal 2023 first quarter financial results. The live webcast can be accessed via Landec's website on the Investor Events & Presentations page. The web
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
Barrington Research upgraded Landec from Mkt Perform to Outperform and set a new price target of $14.00
Stephens initiated coverage of Landec with a rating of Overweight and set a new price target of $13.00
Barrington Research downgraded Landec from Outperform to Mkt Perform
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
SCHEDULE 13G - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol "LFCR" Lifecore global headquarters relocated to Chaska, MN Launches new investor relations website: ir.lifecore.com CHASKA, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has completed its transition to Lifecore Biomedical, including the change of its name from Landec Corporation to Lifecore Biomedical, Inc. In connection with this change, the Company's common stock is also expected to commence trading under its new Nasdaq ticker symbol "LFCR" tomorrow, N
CHASKA, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Lifecore" or the "Company"), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. ("Lifecore") and Curation Foods, Inc. ("Curation Foods"), – today announced that Jim Hall, CEO of Landec Corporation & President of Lifecore, and John Morberg, CFO will be hosting a fireside chat at the Stephens Annual Investment Conference in Nashville, TN. The Company will participate in a fireside chat on Thursday, November 17th at 8:00 AM CT. The live audio webcast will be available to all interested parties through a live audio webcast accessible on the Company's investor rel
CHASKA, Minn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Landec Corporation (NASDAQ:LNDC) ("Lifecore" or the "Company") today announced that it expects to effect its previously announced corporate name change to Lifecore Biomedical, Inc. and to cause its common stock to begin trading on Nasdaq under the ticker symbol "LFCR" prior to market open on November 14, 2022. This new ticker symbol will replace the Company's current ticker symbol "LNDC," which has been used since its initial public offering in 1996. The new corporate name and ticker symbol align with the Company's ongoing strategic transformation toward its high-growth, high-value CDMO business that is focused on the development, fill and f
Custom Made Meals (CMM), a leading national provider of fresh, ready-to-cook (RTC) entrees, appetizers, and sides for the meat and deli departments of retail grocery and club stores, announced today that it has appointed Molly Montgomery as CEO, effective today. Ms. Montgomery has served on the CMM Board of Directors since it was acquired by Stellex Capital Management LLC (Stellex) in May of 2021 and will continue to serve on the board in her new role. Stellex is a middle-market private investment firm with strong experience in the food industry. Ms. Montgomery succeeds Dale Easdon, who has led the Company as CEO for the past three years and has worked closely with management to ensure a sm
SC 13G/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
Landec Corporation (NASDAQ:LNDC) (“Lifecore” or the “Company”) today announced that it expects to effect its previously announced corporate name change to Lifecore Biomedical, Inc. and to cause its common stock to begin trading on Nasdaq under the ticker symbol “LFCR” prior to market open on November 14, 2022. This new ticker symbol will replace the Company’s current ticker symbol “LNDC,” which has been used since its initial public offering in 1996. The new corporate name and ticker symbol align with the Company’s ongoing strategic transformation toward its high-growth, high-value CDMO business that is focused on the development, fill and finish of complex sterile injectable pharmaceutical
Barrington Research analyst Michael Petusky maintains Landec (NASDAQ:LNDC) with a Outperform and lowers the price target from $14 to $12.
Landec (NASDAQ:LNDC) reported its Q1 earnings results on Thursday, October 6, 2022 at 07:15 AM. Here's what investors need to know about the announcement. Earnings Landec missed estimated earnings by 146.15%, reporting an EPS of $-0.32 versus an estimate of $-0.13. Revenue was down $85.43 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.0 which was followed by a 2.63% increase in the share price the next day. Here's a look at Landec's past performance: Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022 EPS Estimate -0.01 -0.04 -0.12 EPS Actual -0.01 -0.08 -0.25 -